Sugi Predict

Sugi Predict / Compounds / SCHEMBL2385585

SCHEMBL2385585

SCHEMBL2385585

CCCCCCCCCCCCCCCCOC(CCCCCCCCCCCCCCCC)C(O)CO

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2D6 P10635 2/20 0.47
▸ LMNA P02545 2/20 0.47
▸ SPHK1 Q9NYA1 2/20 0.47
▸ MAPT P10636 2/20 0.47
▸ HTT P42858 2/20 0.47
▸ GMNN O75496 1/20 0.47
▸ POLB P06746 1/20 0.47
▸ THPO P40225 1/20 0.47
▸ MTOR P42345 1/20 0.47
▸ BLM P54132 1/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ TP53 P04637 1/20 0.47
▸ CYP1A2 P05177 1/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ CETP P11597 1/20 0.47
▸ UBE2N P61088 1/20 0.47
▸ USP2 O75604 1/20 0.46
▸ PTPN1 P18031 1/20 0.44
▸ MGAM O43451 3/20 0.44
▸ ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18139666 1.00 CYP2D6 (0.47) CYP2D6LMNASPHK1MAPTHTT
SCHEMBL9623258 1.00 CYP2D6 (0.47) CYP2D6LMNASPHK1MAPTHTT
SCHEMBL29064944 1.00 CYP2D6 (0.47) CYP2D6LMNASPHK1MAPTHTT
SCHEMBL28434701 1.00 CYP2D6 (0.47) CYP2D6LMNASPHK1MAPTHTT
SCHEMBL5963213 1.00 CYP2D6 (0.47) CYP2D6LMNASPHK1MAPTHTT
SCHEMBL139954 1.00 CYP2D6 (0.47) CYP2D6LMNASPHK1MAPTHTT
SCHEMBL8636200 1.00 CYP2D6 (0.47) CYP2D6LMNASPHK1MAPTHTT
SCHEMBL1890335 1.00 CYP2D6 (0.47) CYP2D6LMNASPHK1MAPTHTT
SCHEMBL142856 1.00 CYP2D6 (0.47) CYP2D6LMNASPHK1MAPTHTT
SCHEMBL28230194 1.00 CYP2D6 (0.47) CYP2D6LMNASPHK1MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10260071-B2 CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity COLEY PHARMACEUTICAL GMBH (DE) 2019-04-16 — — US claimed
US-20160348115-A1 CpG Oligonucleotide Analogs Containing Hydrophobic T Analogs with Enhanced Immunostimulatory Activity PFIZER INC. 2016-12-01 — — US claimed
EP-2078080-B1 CPG OLIGONUCLEOTIDE ANALOGS CONTAINING HYDROPHOBIC T ANALOGS WITH ENHANCED IMMUNOSTIMULATORY ACTIVITY COLEY PHARM GMBH (DE) 2015-06-17 — — EP claimed
US-20140163213-A1 CpG Oligonucleotide Analogs Containing Hydrophobic T Analogs with Enhanced Immunostimulatory Activity COLEY PHARMACEUTICAL GMBH (DE) 2014-06-12 — — US claimed
US-20100166780-A1 CpG Oligonucleotide Analogs Containing Hydrophobic T Analogs with Enhanced Immunostimulatory Activity PFIZER INC 2010-07-01 — — US claimed
EP-2078080-A2 CPG OLIGONUCLEOTIDE ANALOGS CONTAINING HYDROPHOBIC T ANALOGS WITH ENHANCED IMMUNOSTIMULATORY ACTIVITY Coley Pharmaceuticals GmbH (DE) 2009-07-15 — — EP claimed
WO-2008068638-A2 CPG OLIGONUCLEOTIDE ANALOGS CONTAINING HYDROPHOBIC T ANALOGS WITH ENHANCED IMMUNOSTIMULATORY ACTIVITY COLEY PHARMACEUTICAL GMBH (DE) 2008-06-12 — — WO claimed
CN-119790152-A Treatment of neurological disorders using modulators of UNC13A gene transcripts 奎里斯公司 2025-04-08 — — CN disclosed
CN-119365486-A EPO receptor agonists and antagonists 免疫先锋股份有限公司 2025-01-24 — — CN disclosed
CN-119137272-A Renin modulating compositions and methods of use thereof 阿达尔克斯制药有限公司 2024-12-13 — — CN disclosed
CN-115996755-A Bifunctional molecules and methods of use thereof 旗舰创业创新VI有限责任公司 2023-04-21 — — CN disclosed
US-10260071-B2 CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity COLEY PHARMACEUTICAL GMBH (DE) 2019-04-16 — — US disclosed
US-9512162-B2 Synthesis of deuterated ribo nucleosides, N-protected phosphoramidites and oligonucleotides ASED, LLC (US) 2016-12-06 — — US disclosed
EP-0747351-A2 Thiocationic lipids, pharmaceutical compositions and methods of use thereof GEN-PROBE INCORPORATED (US) 1996-12-11 — — EP disclosed
WO-1996034876-A1 NUCLEIC ACID LIGAND COMPLEXES NEXSTAR PHARMACEUTICALS, INC. (US) 1996-11-07 — — WO disclosed
US-5439944-A Red blood cell substitute emulsions containing alkyl- or alkylglyucerophosphoryl choline surfactants and methods of use HEMAGEN/PFC (US) 1995-08-08 — — US disclosed
US-5439669-A Stable physiologically acceptable emulsion of fluorochemical, water, surfactant HEMAGEN/PFC (US) 1995-08-08 — — US disclosed
EP-0663829-A1 EMULSIONS CONTAINING ALKYL- OR ALKYLGYLCEROPHOSPHORYL CHOLINE SURFACTANTS AND METHODS OF USE HEMAGEN/PFC (US) 1995-07-26 — — EP disclosed
US-5304325-A Emulsions of fluorochemical, water, surfactant; synthetic blood HEMAGEN/PFC (US) 1994-04-19 — — US disclosed
WO-1993009787-A1 EMULSIONS CONTAINING ALKYL- OR ALKYLGYLCEROPHOSPHORYL CHOLINE SURFACTANTS AND METHODS OF USE HEMAGEN/PFC (US) 1993-05-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100166780-A1 CpG Oligonucleotide Analogs Containing Hydrophobic T Analogs with Enhanced Immunostimulatory Activity TLR9, TYMP, STING1 CYP2D6 3105/4885LMNA 4419/4885SPHK1 2011/4885
US-10260071-B2 CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity TLR9, TYMP, STING1 CYP2D6 3105/4885LMNA 4419/4885SPHK1 2011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.